ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Thrombopoietin Receptor Agonist

Also written as “thrombopoietin receptor agonist (TPO-RA)” and “PN20 treatment”.

Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic, led by 2 companies.

Drug pageThrombopoietin Receptor Agonist: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 11, 20252 company-led studies, 1 open or runningNext primary completion: Jan 18, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Peg-Bio Biopharmits history only10 open or runningphase 1since Mar 11, 2025Mar 11, 2025none ahead
Novartisits history only11 open or runningphase 2since Feb 12, 2026Feb 12, 2026Jan 18, 2029phase 2 · NCT07421167

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 25, 2022Named thrombopoietin receptor agonistINNProposed as its International Nonproprietary Name in WHO's List 126
  2. Mar 11, 2025First study: phase 1 study in Purpura, Thrombocytopenic, IdiopathicNew to Chongqing Peg-Bio BiopharmChongqing Peg-Bio Biopharm · NCT06880081 · 12 enrolled · China
  3. Feb 12, 2026Novartis’s first study: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNew to NovartisNovartis · NCT07421167 · 164 planned · United States

Ahead

  1. Jan 18, 2029Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNovartis · NCT07421167

TargetBeta

TPO →read by rule
“Any agent that binds to and activates the thrombopoietin (TPO) receptor.”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07421167Purpura, Thrombocytopenic, Idiopathic · United States2RecruitingNovartisJan 18, 2029164
NCT06880081Purpura, Thrombocytopenic, Idiopathic · China1CompletedChongqing Peg-Bio BiopharmFeb 14, 202612

How it is read

Names in the registry

  • “thrombopoietin receptor agonist (TPO-RA)”, 1 entry
  • “PN20 treatment”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.